Abstract:Integrin αIIbβ3 (previously called glycoprotein [GP] IIb/IIIa) is a transmembrane GP receptor, which plays a crucial role in blood coagulation by mediating platelet aggregation.[1] [2] After activation, this receptor initiates platelet aggregation rapidly through changing its conformation and introducing the interaction of platelets with a wide array of ligands such as fibrinogen, fibronectin, and von Willebrand factor (VWF). Germline mutations in genes encoding the subunits of the complex, integrin subunit α 2b ( ITGA2B ) and integrin subunit β 3 ( ITGB3 ), have been reported mainly in the platelet-type bleeding disorder Glanzmann thrombasthenia (GT).[3] GT is a congenital disease that follows an autosomal recessive inheritance pattern and exhibits failure or deficiency of platelet aggregation, although with normal platelet counts and morphology.[4] However, several αIIbβ3 variants have also been identified in patients with congenital macrothrombocytopenia, a genetically heterogeneous group of rare disorders characterized by abnormal giant platelets, reduction of platelets, and bleeding tendency with variable severity.[5] Our case is a 13-year-old boy who was referred to our hospital because of hemostatic difficulty after a first episode of epistaxis. His platelet count was 79 × 10 9 /L (normal range: 150–407 × 10 9 /L); the mean platelet volume (MPV) and platelet distribution width (PDW) were close to the upper limit of the reference intervals (MPV: 13.7fL, normal range: 9.0–13.8 fL, PDW: 21.5 fL, normal range: 9.8–21.9 fL). Six months later, the patient was referred to our hospital again due to sporadic petechia of skin. At that time, routine blood test of the patient showed mild reduction in platelet count (102 × 10 9 /L), with no abnormalities of MPV (12.9 fL) and PDW (18.6 fL). His blood cell smear identified a few giant platelets (4 in a standard automated smear in Mindray blood analyzer MC-80), while without obvious reduction of cytoplasmic granules ([Fig. 1A] and [B]). Except for a slight rise near the upper boundary of activated partial thromboplastin time (37.0 seconds; normal range: 25.1–36.5 seconds), other coagulation indicators, including prothrombin time (PT), prothrombin activity, fibrinogen, thrombin time (TT), and international normalized ratio, were all within normal ranges. VWF level and activity were also within normal limits. Platelet aggregation induced by adenosine diphosphate (ADP), collagen, adrenalin, or arachidonate were each substantially reduced ([Fig. 2A]), to varying degrees (ADP: 9.1%, collagen: 17.7%, adrenalin: 28.6%, arachidonate: 1.0%), whereas aggregation induced by ristomycin (ristocetin) was close to normal level (52.2%, [Fig. 2B]), only slightly lower than the bottom of normal range (55.0–100.0%). In addition, tests for autoimmune antibodies were negative for common anti-platelet antibodies, including GPIX (CD42a), GPIB (CD42b), GPIIB (CD41), GPIIIA (CD61), and GMP140 (CD61p). Detailed laboratory results are summarized in [Table 1]. Assays Proband's results Reference interval Blood cell counts[a] Platelet count, ×10 9 /L 102.0 150.0–407.0 MPV, fL 12.9 9.0–13.8 PDW, fL 18.6 9.8–21.9 Thrombosis/hemostasis tests[b] PT, s 12.3 9.4–12.5 Prothrombin activity, % 97 80–130 INR 1.04 0.85–1.15 Fibrinogen, g/L 2.52 2.38–4.98 aPTT, s 37.0 25.1–36.5 TT, s 15.1 10.3–16.6 VWF assays[c] VWF:Ag (activity), % 111 50–200 VWF:Ag (level), % 105 50–200 VWF:Ag (activity)/VWF:Ag (level) ratio 1.06 Platelet aggregation[d] ADP (6 μM), % 9.1 50.0–100.0 Collagen (5 mg/L), % 17.7 55.0–100.0 Adrenalin (180 μM), % 28.6 55.0–100.0 Arachidonate (0.3 g/L), % 1.0 55.0–100.0 Ristomycin (1.5 g/L), % 52.2 55.0–100.0 Abbreviations: ADP, adenosine diphosphate; aPTT, activated partial thromboplastin time; INR, international normalized ratio; MPV, mean platelet volume; PDW, platelet distribution width; PT, prothrombin time; TT, thrombin time; VWF, von Willebrand factor. a The analysis of blood routine test was accomplished on Mindray CAL8000 hematology system. b The coagulation indicators PT, aPTT, TT, and fibrinogen were determined by coagulation assays using corresponding STA reagents (Diagnostica Stago, France) on a STA MAX automatic coagulation analyzer (Diagnostica Stago, France) according to the manufacturer's instructions. The indicators prothrombin activity and INR were calculated based on the result of PT. c The VWF antigen activity and level were detected by immunoturbidimetric assay using HemosIL VWF activity or antigen kits on ACL TOP 700 automatic coagulation analyzer (Instrumentation Laboratory, United States). d The platelet aggregation tests were conducted by optical turbidimetric assay using Helena platelet aggregation -Abstract Truncated-

[A preliminary study of an inherited macrothrombocytopenia disorder with abnormal large granules]

An Inherited Macrothrombocytopenic Disorder with Abnormal Large Granules.

Giant electron-dense chains, clusters and granules in megakaryocytes and platelets with normal dense bodies: an inherited thrombocytopenic disorder I. Megakaryocytes

A novel frameshift GP1BB mutation causes autosomal dominant macrothrombocytopenia with decreased vWF receptor expression but normal platelet aggregation

Hereditary thrombocytopenia with platelet sialic acid deficiency and mutations in the GNE genes

Advances in understanding the pathogenesis of hereditary macrothrombocytopenia

An ultrastructural morphometric analysis of platelet giant and fusion granules

Identification of a pathogenic <i>TUBB1</i> variant in a Chinese family with congenital macrothrombocytopenia through whole genome sequencing

Heterozygous ITGA2B Phe1024 Deletion Associated with Abnormal αIIbβ3 Function in a Patient with Congenital Thrombocytopenia

Biological, clinical features and modelling of heterozygous variants of glycoprotein Ib platelet subunit alpha (GP1BA) and glycoprotein Ib platelet subunit beta (GP1BB) genes responsible for constitutional thrombocytopenia

Advances in our understanding of the molecular basis of disorders of platelet function

Marked Underestimation of Platelet Count and a Characteristic Platelet Histogram as Clues to MYH9-Related Disorders

Severe Congenital Thrombocytopenia Characterized by Decreased Platelet Sialylation and Moderate Complement Activation Caused by Novel Compound Heterozygous Variants in GNE

Mechanisms of thrombocytopenia in platelet-type von Willebrand disease

Megakaryocyte migration defects due to nonmuscle myosin IIA mutations underlie thrombocytopenia in MYH9-related disease

Inherited traits affecting platelet function

Dominant inheritance of a novel integrin beta3 mutation associated with a hereditary macrothrombocytopenia and platelet dysfunction in two Italian families

Rare variants in GP1BB are responsible for autosomal dominant macrothrombocytopenia.

Inherited platelet diseases with normal platelet count: phenotypes, genotypes and diagnostic strategy

Evaluation of Platelet Count by the SYSMEX XE-2100 Blood cell Analyzer in Giant platelet Disease

A Novel GATA1 Variant P.g229d Causing the Defect of Procoagulant Platelet Formation